融捷健康(300247) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥102,969,850.43, representing an increase of 8.94% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2023 was ¥4,648,112.77, a significant increase of 25.18% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥4,276,300.66, up 4.49% from the previous year[5]. - Total operating revenue for the current period reached ¥374,171,590.65, an increase of 13.14% compared to ¥330,663,140.51 in the previous period[32]. - Net profit for the current period was ¥38,691,932.62, a decrease of 73.5% from ¥146,229,493.28 in the previous period[34]. - Operating profit decreased to ¥49,683,497.68 from ¥154,732,798.88, representing a decline of 67.9%[34]. - Total comprehensive income for the current period was ¥43,526,385.90, down from ¥191,420,496.12, indicating a decline of 77.25%[34]. - The company's basic earnings per share for Q3 2023 was ¥0.0058, an increase of 26.09% year-on-year[5]. - The company reported a basic earnings per share of ¥0.0319, compared to ¥0.1718 in the previous period, reflecting a decrease of 81.4%[34]. Assets and Liabilities - The total assets at the end of Q3 2023 amounted to ¥1,207,725,560.77, reflecting a growth of 1.76% compared to the end of the previous year[5]. - As of September 30, 2023, total current assets amount to 803,937,267.25 CNY, an increase from 766,734,840.18 CNY at the beginning of the year, representing a growth of approximately 4.3%[29]. - The total assets as of September 30, 2023, are 1,207,725,560.77 CNY, compared to 1,186,803,628.67 CNY at the beginning of the year, reflecting an increase of approximately 1.8%[31]. - Total liabilities decreased to 135,425,873.14 CNY from 158,030,326.94 CNY, a reduction of about 14.3%[30]. - The company's total equity increased to 1,072,299,687.63 CNY from 1,028,773,301.73 CNY, indicating a growth of about 4.2%[31]. Cash Flow - The cash flow from operating activities for the year-to-date period increased by 250.01% to ¥81,659,647.96[5]. - The net cash flow from operating activities increased by ¥136,096,000.00 compared to the same period last year, primarily due to increased sales revenue[26]. - Cash flow from operating activities generated a net amount of ¥81,659,647.96, a significant recovery from a negative cash flow of ¥54,436,363.18 in the previous period[36]. - Cash and cash equivalents increased to 114,555,168.95 CNY from 68,300,201.59 CNY, marking a growth of approximately 67.7%[29]. - Cash and cash equivalents at the end of the period totaled ¥114,555,168.95, a significant increase from ¥21,678,949.24 at the end of the previous period[36]. - Investment activities resulted in a net cash outflow of ¥28,646,321.39, compared to a smaller outflow of ¥13,875,248.94 in the previous period[36]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 35,360[27]. - The largest shareholder, Rongjie Investment Holding Group Co., Ltd., holds 14.54% of shares, totaling 116,912,302 shares[27]. - The company has no preferred shareholders as of the reporting period[28]. Operational Highlights - The company reported a decrease in accounts receivable by ¥11,605,500.00, a decline of 29.63% due to the recovery of previous receivables[10]. - The company experienced a decrease in inventory by ¥44,060,500.00, a drop of 23.62%, attributed to the sale of last year's stock[13]. - The company is focusing on expanding its market presence and developing new technologies, although specific details were not disclosed in the report[30]. Investment Income - The company reported a decrease in investment income of ¥130,824,500.00 compared to the previous year, as there were no equity transfer gains in the current period[19]. Audit Status - The third quarter report of Rongjie Health Technology Co., Ltd. is unaudited[38].